Health service adds caveat saying that performance improvements cannot be attributed to £330mn contract
The NHS England's admission follows scrutiny over large public sector contracts with tech companies and the ongoing debate about the efficacy and value for money of AI in healthcare.
This highlights the challenges in proving tangible benefits from significant government investments in advanced technology, particularly for highly sensitive and complex public services like healthcare.
The perceived effectiveness and accountability of large-scale AI contracts in public health systems are now under increased scrutiny, potentially influencing future procurement decisions and vendor selection.
- · Ethical AI advocates
- · Evidence-based policy makers
- · Alternative healthcare analytics providers
- · Palantir
- · AI contractors in public sector
- · Proponents of rapid AI adoption in healthcare
NHS England faces pressure to justify the £330mn Palantir contract amidst claims of unproven effectiveness.
Other governments may increase their due diligence and demand more robust evidence of impact before awarding large AI contracts, especially in critical sectors.
This could lead to a shift in procurement models for public sector technology, focusing more on outcome-based agreements and independent validation rather than vendor promises.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Financial Times — Technology